Cellular immunotherapy for refractory hematological malignancies

BACKGROUND: Acute myeloid leukemia (AML) and other aggressive refractory hematological malignancies unresponsive to upfront therapy remain difficult conditions to treat. Often, the focus of therapy is centered on achieving complete remission of disease in order to proceed with a consolidative stem c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Reagan, John L, Fast, Loren D, Safran, Howard, Nevola, Martha, Winer, Eric S, Castillo, Jorge J, Butera, James N, Quesenberry, Matthew I, Young, Carolyn T, Quesenberry, Peter J
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3689050/
https://ncbi.nlm.nih.gov/pubmed/23782682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-150
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados